Vincenzi B - Search Results

1

Immunotherapy in Hepatocellular Carcinoma.

Fulgenzi CAM, Talbot T, Murray SM, Silletta M, Vincenzi B, Cortellini A, Pinato DJ. Fulgenzi CAM, et al. Among authors: vincenzi b. Curr Treat Options Oncol. 2021 Aug 23;22(10):87. doi: 10.1007/s11864-021-00886-5. Curr Treat Options Oncol. 2021. PMID: 34424422 Free PMC article. Review.

2

Cell cycle alterations and lung cancer.

Vincenzi B, Schiavon G, Silletta M, Santini D, Perrone G, Di Marino M, Angeletti S, Baldi A, Tonini G. Vincenzi B, et al. Histol Histopathol. 2006 Apr;21(4):423-35. doi: 10.14670/HH-21.423. Histol Histopathol. 2006. PMID: 16437388 Review.

3

Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G. Vincenzi B, et al. Ann Oncol. 2006 May;17(5):835-41. doi: 10.1093/annonc/mdl031. Epub 2006 Feb 28. Ann Oncol. 2006. PMID: 16507564 Free article.

4

The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies.

Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. Vincenzi B, et al. Expert Opin Emerg Drugs. 2006 Nov;11(4):665-83. doi: 10.1517/14728214.11.4.665. Expert Opin Emerg Drugs. 2006. PMID: 17064225 Review.

5

Antiangiogenic properties of metronomic chemotherapy in breast cancer.

Tonini G, Schiavon G, Silletta M, Vincenzi B, Santini D. Tonini G, et al. Among authors: vincenzi b. Future Oncol. 2007 Apr;3(2):183-90. doi: 10.2217/14796694.3.2.183. Future Oncol. 2007. PMID: 17381418 Review.

6

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.

Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G. Vincenzi B, et al. Clin Cancer Res. 2008 Jul 1;14(13):4219-24. doi: 10.1158/1078-0432.CCR-08-0077. Clin Cancer Res. 2008. PMID: 18594003 Free article.

7

The biological properties of cetuximab.

Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. Vincenzi B, et al. Crit Rev Oncol Hematol. 2008 Nov;68(2):93-106. doi: 10.1016/j.critrevonc.2008.07.006. Epub 2008 Aug 3. Crit Rev Oncol Hematol. 2008. PMID: 18676156 Review.

8

PML down-regulation in soft tissue sarcomas.

Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G. Vincenzi B, et al. J Cell Physiol. 2010 Sep;224(3):644-8. doi: 10.1002/jcp.22161. J Cell Physiol. 2010. PMID: 20578240

9

PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.

Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G. Vincenzi B, et al. J Cell Physiol. 2012 Apr;227(4):1657-62. doi: 10.1002/jcp.22889. J Cell Physiol. 2012. PMID: 21678421

10

Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.

Vincenzi B, Napolitano A, D'Onofrio L, Frezza AM, Silletta M, Venditti O, Santini D, Tonini G. Vincenzi B, et al. Expert Opin Investig Drugs. 2011 Dec;20(12):1685-705. doi: 10.1517/13543784.2011.628984. Epub 2011 Oct 20. Expert Opin Investig Drugs. 2011. PMID: 22010859 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

491 results

Search Page